Severe Mitral Regurgitation and Cardiogenic Shock: Is Edge-to-Edge a Valid Strategy?

At present, cardiogenic shock continues to present high mortality despite the new treatments and ventricular assistance devices available in some centers. 

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

In this group, the presence of severe mitral regurgitation (MR) is around 5% and, on many occasions, it cannot be treated with surgery because of hemodynamic conditions. 

Edge-to-edge repair has been looked at by several studies with promising results. 

This study looked at patients from the STS/ACC, a registry of patients with cardiogenic shock and severe MR undergoing edge-to-edge repair with MitraClip. 

It included 3,797 patients. 3,249 (85.6%) were successfully implanted.

The populations were similar, mean age was 73, 60% were men, 80% were hypertensive, 2% had endocarditis, 37% prior MI, 35% prior PCI, and 64% atrial fibrillation.

MR was degenerative in 53,4% and STS was 15%.

Read also: IVUS Use in Peripheral Vascular Disease: Should this Tool Be Used More Frequently in Peripheral Interventions?

At 30 days, procedural complications were quite low, with no differences, but mortality was higher in those presenting device failure (16.4% vs. 9.1% p<0.001), as well as lower hospital stay (14.3 vs. 12.2 days p<0.001).

At one-year followup, mortality was lower among the successfully implanted (34.6% vs 55.5%; P < 0.001), with a number needed to treat (NNT) of 4.8 patients. Likewise, the combination of mortality and hospitalization for cardiac failure was lower in this group (29.6% vs 45.2%; P <0.001; NNT 6.4).

Conclusion

Reducing mitral regurgitation was possible in most patients with cardiogenic shock and was associated with significantly lower mortality and hospitalization for cardiac failure. Further randomized studies on Edge- to-edge in patients with cardiogenic shock are needed to establish the potential of this treatment. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter Edge-to-Edge Mitral Valve Repair in Patients With Severe Mitral Regurgitation and Cardiogenic Shock.

Reference: Trevor Simard, et al. J Am Coll Cardiol 2022;80:2072–2084.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...